Valuation: Axonics, Inc.

Market Cap 3.63B 3.17B 2.93B 2.7B 5.08B 349B 5.2B 34.97B 13.75B 171B 13.62B 13.33B 589B P/E 2022
-48.9x
P/E 2023 -502x
Enterprise Value 3.31B 2.89B 2.67B 2.46B 4.64B 319B 4.74B 31.91B 12.55B 156B 12.43B 12.16B 537B EV / Sales 2022
10x
EV / Sales 2023 7.74x
Free-Float
99.8%
Yield 2022 *
-
Yield 2023 -
3 years 48.3
Extreme 48.3
71.05
5 years 38.41
Extreme 38.41
79.92
10 years 11.95
Extreme 11.95
79.92
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/10/2013
Director of Finance/CFO 41 02/10/2023
Chief Operating Officer 47 01/08/2018
Director TitleAgeSince
Director/Board Member 69 01/02/2018
Chairman 55 29/04/2020
Director/Board Member 74 08/04/2019
Date Insider Type Main position Quantity % Market Cap.
11/15/24 A Issuer sale

Executive/Senior Manager

59,355 0.1161%
11/15/24 A Issuer sale

Director

29,111 0.0569%
11/15/24 A Issuer sale

Director

19,542 0.0382%
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%-.--%-.--%+39.23% 3.63B
-3.42%-3.01%-17.86%+7.83% 123B
-1.03%+0.96%+2.31%-2.04% 13.04B
+0.93%+2.69%+60.52%+99.12% 9.21B
+3.09%+12.41%-43.39%-68.31% 4.47B
-6.27%-0.13%+5.35%+45.65% 2.7B
-6.41%-7.36%-22.63%-31.72% 1.62B
-4.80%-0.43%-12.90%-21.55% 1.6B
-3.56%+5.13%+2.97%-58.53% 1.56B
Average -2.30%+2.02%-2.85%+1.08% 17.83B
Weighted average by Cap. -2.79%-1.63%-11.43%+10.16%

Financials

2022 2023
Net sales 274M 239M 221M 203M 383M 26.36B 392M 2.64B 1.04B 12.91B 1.03B 1.01B 44.44B 366M 320M 295M 272M 513M 35.28B 525M 3.53B 1.39B 17.28B 1.38B 1.35B 59.49B
Net income -59.7M -52.17M -48.14M -44.37M -83.64M -5.75B -85.49M -575M -226M -2.82B -224M -219M -9.69B -6.09M -5.32M -4.91M -4.53M -8.53M -586M -8.72M -58.68M -23.08M -287M -22.86M -22.36M -988M
Net Debt -348M -304M -281M -259M -488M -33.52B -499M -3.36B -1.32B -16.42B -1.31B -1.28B -56.52B -317M -277M -256M -236M -445M -30.56B -454M -3.06B -1.2B -14.97B -1.19B -1.17B -51.52B
Logo Axonics, Inc.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Employees
797
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. AXNX Stock